FDA recognizes psilocybin as ‘breakthrough therapy’ for depression

The only reference to psilocybin on the Food and Drug Administration’s website appears in the agency’s Bad Bug Book: Handbook of Foodborne Pathogenic Microorganisms and Natural Toxins, where the psychedelic compound is described as a “neurotoxin” found in mushrooms. 

The FDA’s dueling portrayals of psilocybin as a scary fungal neurotoxin and a promising treatment for depression are part of a broader story about forbidden drugs, including MDMA, marijuana, and LSD, whose benefits scientists are once again studying with government approval after decades of neglect. The rehabilitation of these substances, which may ultimately make them available as prescription drugs, is a far cry from the pharmacological freedom that libertarians favor. But it represents a welcome return to empiricism in an area of public policy long driven by irrational prejudice.

Original Article (Reason):
FDA Recognizes Psilocybin As ‘Breakthrough Therapy’ for Depression
Artwork Fair Use: ECfES.org

What is kratom…?

Kratom LD-50 Stats

Science

Change, grow, live

Rolling in the deep

The Peace Drug

Leave a Reply